Format
Sort by

Send to

Choose Destination

Search results

Items: 8

1.

The influence of insulin-like Growth Factor-1-Receptor expression and endocrine treatment on clinical outcome of postmenopausal hormone receptor positive breast cancer patients: A Dutch TEAM substudy analysis.

Engels CC, de Glas NA, Sajet A, Bastiaannet E, Smit VT, Kuppen PJ, Seynaeve C, van de Velde CJ, Liefers GJ.

Mol Oncol. 2016 Apr;10(4):509-16. doi: 10.1016/j.molonc.2015.10.010. Epub 2015 Oct 31.

PMID:
26706833
2.

The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis.

Engels CC, Charehbili A, van de Velde CJ, Bastiaannet E, Sajet A, Putter H, van Vliet EA, van Vlierberghe RL, Smit VT, Bartlett JM, Seynaeve C, Liefers GJ, Kuppen PJ.

Breast Cancer Res Treat. 2015 Feb;149(3):587-96. doi: 10.1007/s10549-015-3269-7. Epub 2015 Jan 24.

3.

High nuclear expression levels of histone-modifying enzymes LSD1, HDAC2 and SIRT1 in tumor cells correlate with decreased survival and increased relapse in breast cancer patients.

Derr RS, van Hoesel AQ, Benard A, Goossens-Beumer IJ, Sajet A, Dekker-Ensink NG, de Kruijf EM, Bastiaannet E, Smit VT, van de Velde CJ, Kuppen PJ.

BMC Cancer. 2014 Aug 20;14:604. doi: 10.1186/1471-2407-14-604.

4.

Expression of cell adhesion molecules and prognosis in breast cancer.

Saadatmand S, de Kruijf EM, Sajet A, Dekker-Ensink NG, van Nes JG, Putter H, Smit VT, van de Velde CJ, Liefers GJ, Kuppen PJ.

Br J Surg. 2013 Jan;100(2):252-60. doi: 10.1002/bjs.8980. Epub 2012 Nov 22.

PMID:
23175431
5.

Age determines the prognostic role of the cancer stem cell marker aldehyde dehydrogenase-1 in breast cancer.

Mieog JS, de Kruijf EM, Bastiaannet E, Kuppen PJ, Sajet A, de Craen AJ, Smit VT, van de Velde CJ, Liefers GJ.

BMC Cancer. 2012 Jan 26;12:42. doi: 10.1186/1471-2407-12-42.

6.

NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study.

de Kruijf EM, Sajet A, van Nes JG, Putter H, Smit VT, Eagle RA, Jafferji I, Trowsdale J, Liefers GJ, van de Velde CJ, Kuppen PJ.

BMC Cancer. 2012 Jan 18;12:24. doi: 10.1186/1471-2407-12-24.

7.

HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients.

de Kruijf EM, Sajet A, van Nes JG, Natanov R, Putter H, Smit VT, Liefers GJ, van den Elsen PJ, van de Velde CJ, Kuppen PJ.

J Immunol. 2010 Dec 15;185(12):7452-9. doi: 10.4049/jimmunol.1002629. Epub 2010 Nov 5.

8.

The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer.

de Kruijf EM, van Nes JG, Sajet A, Tummers QR, Putter H, Osanto S, Speetjens FM, Smit VT, Liefers GJ, van de Velde CJ, Kuppen PJ.

Clin Cancer Res. 2010 Feb 15;16(4):1272-80. doi: 10.1158/1078-0432.CCR-09-1844. Epub 2010 Feb 9.

Items per page

Supplemental Content

Write to the Help Desk